National Pension Service Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• The National Pension Service has increased its ownership of Regeneron Pharmaceuticals by 8.9% in the first quarter, owning approximately 0.23% of the company with a value of $160.5 million.
• Analyst ratings for Regeneron show a mixed outlook, with one "sell," seven "hold," and sixteen "buy" ratings, alongside varying price targets ranging from $547.00 to $850.00.
• Regeneron Pharmaceuticals reported a quarterly earnings per share of $12.89, significantly above the consensus estimate of $8.43, and a revenue of $3.68 billion, showing a 3.6% increase compared to the previous year.

National Pension Service raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 253,046 shares of the biopharmaceutical company's stock after purchasing an additional 20,596 shares during the period. National Pension Service owned approximately 0.23% of Regeneron Pharmaceuticals worth $160,489,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the period. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $27,000. Tompkins Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $32,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

REGN has been the topic of several analyst reports. Bank of America decreased their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Citigroup reiterated a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. The Goldman Sachs Group decreased their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $835.74.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $561.55 on Thursday. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The business's 50 day moving average price is $540.81 and its 200-day moving average price is $597.08. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock has a market cap of $59.52 billion, a P/E ratio of 14.15, a P/E/G ratio of 1.88 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the previous year, the firm posted $11.56 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.